Highlights
The Evaluating Liraglutide in Alzheimer’s Disease (ELAD) phase 2b trial found no significant difference in the primary endpoint of cerebral glucose metabolic rate between liraglutide and placebo groups over 52 weeks. Secondary endpoints revealed a statistically significant benefit in the Alzheimer’s Disease Assessment Scale-Executive domain (ADAS-Exec) for patients treated with liraglutide. Liraglutide demonstrated a favorable safety profile in non-diabetic patients with Alzheimer’s disease, consistent with its known clinical profile in metabolic medicine. The study underscores the complexity of using metabolic markers as proxies for clinical cognitive outcomes in neurodegenerative research.
